438 related articles for article (PubMed ID: 16837676)
1. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.
Barrett-Connor E; Mosca L; Collins P; Geiger MJ; Grady D; Kornitzer M; McNabb MA; Wenger NK;
N Engl J Med; 2006 Jul; 355(2):125-37. PubMed ID: 16837676
[TBL] [Abstract][Full Text] [Related]
2. Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial.
Ensrud K; LaCroix A; Thompson JR; Thompson DD; Eastell R; Reid DM; Vukicevic S; Cauley J; Barrett-Connor E; Armstrong R; Welty F; Cummings S
Circulation; 2010 Oct; 122(17):1716-24. PubMed ID: 20937977
[TBL] [Abstract][Full Text] [Related]
3. Lessons from RUTH.
Pines A
Climacteric; 2006 Oct; 9(5):323-4. PubMed ID: 17000580
[TBL] [Abstract][Full Text] [Related]
4. Safety assessment of raloxifene over eight years in a clinical trial setting.
Martino S; Disch D; Dowsett SA; Keech CA; Mershon JL
Curr Med Res Opin; 2005 Sep; 21(9):1441-52. PubMed ID: 16197663
[TBL] [Abstract][Full Text] [Related]
5. Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial.
Barrett-Connor E; Cauley JA; Kulkarni PM; Sashegyi A; Cox DA; Geiger MJ
J Bone Miner Res; 2004 Aug; 19(8):1270-5. PubMed ID: 15231013
[TBL] [Abstract][Full Text] [Related]
6. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
Martino S; Cauley JA; Barrett-Connor E; Powles TJ; Mershon J; Disch D; Secrest RJ; Cummings SR;
J Natl Cancer Inst; 2004 Dec; 96(23):1751-61. PubMed ID: 15572757
[TBL] [Abstract][Full Text] [Related]
7. Effect of Raloxifene on all-cause mortality.
Grady D; Cauley JA; Stock JL; Cox DA; Mitlak BH; Song J; Cummings SR
Am J Med; 2010 May; 123(5):469.e1-7. PubMed ID: 20399327
[TBL] [Abstract][Full Text] [Related]
8. Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy.
Johnell O; Cauley JA; Kulkarni PM; Wong M; Stock JL
J Fam Pract; 2004 Oct; 53(10):789-96. PubMed ID: 15469774
[TBL] [Abstract][Full Text] [Related]
9. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
Ganz PA; Land SR
Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
[TBL] [Abstract][Full Text] [Related]
10. Raloxifene and risk for stroke based on the framingham stroke risk score.
Barrett-Connor E; Cox DA; Song J; Mitlak B; Mosca L; Grady D
Am J Med; 2009 Aug; 122(8):754-61. PubMed ID: 19540454
[TBL] [Abstract][Full Text] [Related]
11. Benefits and risks of raloxifene by vertebral fracture status.
Sontag A; Wan X; Krege JH
Curr Med Res Opin; 2010 Jan; 26(1):71-6. PubMed ID: 19908937
[TBL] [Abstract][Full Text] [Related]
12. Raloxifene use in clinical practice: efficacy and safety.
Goldstein SR; Duvernoy CS; Calaf J; Adachi JD; Mershon JL; Dowsett SA; Agnusdei D; Stuenkel CA
Menopause; 2009; 16(2):413-21. PubMed ID: 19092711
[TBL] [Abstract][Full Text] [Related]
13. Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis.
Silverman SL; Delmas PD; Kulkarni PM; Stock JL; Wong M; Plouffe L
J Am Geriatr Soc; 2004 Sep; 52(9):1543-8. PubMed ID: 15341559
[TBL] [Abstract][Full Text] [Related]
14. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
15. Risk-benefit profiles of raloxifene for women.
Stefanick ML
N Engl J Med; 2006 Jul; 355(2):190-2. PubMed ID: 16837684
[No Abstract] [Full Text] [Related]
16. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.
Lippman ME; Cummings SR; Disch DP; Mershon JL; Dowsett SA; Cauley JA; Martino S
Clin Cancer Res; 2006 Sep; 12(17):5242-7. PubMed ID: 16951244
[TBL] [Abstract][Full Text] [Related]
17. [Raloxifene (Celvista, Evista)].
Body JJ; Sternon J
Rev Med Brux; 2000 Feb; 21(1):35-41. PubMed ID: 10748686
[TBL] [Abstract][Full Text] [Related]
18. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
Shintani M
Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
[TBL] [Abstract][Full Text] [Related]
19. Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis.
Ensrud K; Genazzani AR; Geiger MJ; McNabb M; Dowsett SA; Cox DA; Barrett-Connor E
Am J Cardiol; 2006 Feb; 97(4):520-7. PubMed ID: 16461049
[TBL] [Abstract][Full Text] [Related]
20. [Selective estrogen receptor modulators (SERMs)].
Matsumoto T
Clin Calcium; 2006 Sep; 16(9):1520-25. PubMed ID: 16951478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
